SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Recruiting · NCT04563520 · Registry updated 2026-08-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 3 | 2026-08-21 | NCT04563520 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| Takeda Pharmaceuticals North America, Inc. | 3 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Healthcare of Atlanta | Atlanta | United States | 47 |
| Emory University Hospital | Atlanta | United States | 131 |